Ter Arkh. 2026 Mar 7;98(2):125-130. doi: 10.26442/00403660.2026.02.203532.
ABSTRACT
Coronary heart disease is one of the leading causes of death worldwide, and antiaggregant therapy is crucial for both its prevention and treatment. The review article presents the data of clinical trials that allow to determine the tactics of management of patients at high risk of gastrointestinal complications on the background of dual antiaggregant therapy. The main risk factors for complications are described, such as: acetylsalicylic acid dose, ulcer or bleeding from the upper GI tract in anamnesis, advanced age, concomitant use of anticoagulants, non-aspirin non-steroidal anti-inflammatory drugs, including COX-2-selective non-steroidal anti-inflammatory drugs, Helicobacter pylori infection. The mechanism of action of antiaggregant drugs and pathogenesis of their damaging effect on the GI mucosa, the use of gastroprotective therapy for the prevention and treatment of existing damage to the GI mucosa are considered.
PMID:41801032 | DOI:10.26442/00403660.2026.02.203532